Updated Jul 16, 2026
Miller Deborah Ann has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $15.94M.
Deborah Ann Miller is associated with Nuvalent, Inc., a biotechnology company focused on developing targeted therapies for cancer treatment. Specific details about her role or contributions at the company are not widely documented in public sources.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 14.3K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | A — Grant or award | 14.3K | $0.00 | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 41.1K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | J — Other acquisition / disposition | 18.5K | $124.00 | $2.30M |
| 2026-06-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.7K | $109.30 | $182K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 900 | $108.14 | $97K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.5K | $107.45 | $164K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.4K | $106.32 | $149K |
| 2026-06-01 | NUVL | Nuvalent, Inc. | M — Option exercise | 5.5K | $6.89 | $38K |
| 2026-05-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.1K | $99.57 | $108K |
| 2026-05-01 | NUVL | Nuvalent, Inc. | S — Open-market sale | 4.4K | $99.13 | $438K |
| 2026-05-01 | NUVL | Nuvalent, Inc. | M — Option exercise | 5.5K | $6.89 | $38K |
| 2026-03-30 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 2.8K | $99.46 | $279K |
| 2026-03-30 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 1.8K | $98.21 | $173K |
| 2026-03-30 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 940 | $97.50 | $92K |
| 2026-03-30 | NUVL | Nuvalent, Inc. | M — Option exercise [10b5-1] | 5.5K | $6.89 | $38K |
| 2026-03-02 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 200 | $103.96 | $21K |
| 2026-03-02 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 2.6K | $103.41 | $269K |
| 2026-03-02 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 2.7K | $102.64 | $277K |
| 2026-03-02 | NUVL | Nuvalent, Inc. | M — Option exercise [10b5-1] | 5.5K | $6.89 | $38K |
Deborah Ann Miller is associated with Nuvalent, Inc., a biotechnology company focused on developing targeted therapies for cancer treatment. Specific details about her role or contributions at the company are not widely documented in public sources.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 44 open-market sales ($15.94M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Miller Deborah Ann profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.